BONUS EPISODE: Understanding genetic kidney risk in South Asian populations - sponsored by Alnylam Pharmaceuticals
Talking General PracticeShow Notes
In this special bonus episode Talking General Practice speaks to consultant nephrologist Dr Shafi Malik about the heightened risk of genetic kidney conditions among South Asian populations.
In this conversation, Dr Malik explains why patients of South Asian origin are more at risk of genetic kidney disease and how common these conditions are. He talks specifically about primary hyperoxaluria type 1 (PH1), the symptoms patients might present with if they have this condition - including recurrent kidney stones - and, as kidney stones are a common presentation, how healthcare professionals can recognise when these cases may warrant further investigation.
This episode was presented by GPonline editor Emma Bower. It was produced by Czarina Deen.
This episode of Talking General Practice has been funded by Alnylam Pharmaceuticals and produced in collaboration with GPonline. It is intended for UK healthcare professionals only.
Useful links ThinkPH1.eu National Kidney Federation – PH1
About Alnylam Pharmaceuticals Alnylam is a leading biopharmaceutical company and the pioneer in RNA interference (RNAi), a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam has translated the Nobel Prize-winning science of RNAi into an innovative class of medicines, with the belief that the RNAi approach to treating disease has the potential to help people around the world live longer, healthier and more fulfilling lives.
Hosted on Acast. See acast.com/privacy for more information.
More from Talking General Practice
This week Emma speaks to Professor Andy Brooks and Dr Liam Loftus from the National Association of Primary Care, about the drive towards neighbourhood health and what it means for general practice. Andy is the NAPC’s clinical chair and Liam is head of policy at the organisation.
This week Emma and Nick look at a whole host of GP contract issues, including changes to the GP reimbursement scheme, an update on list cleaning, NHS England threatening possible contractual action over same-day access and what GPs want from next year’s contract.
This week Emma speaks to Dr Adrian Hayter, a GP partner in Windsor and Chief Medical Officer at NICE. Adrian discusses why he made the move to NICE and what having a practicing GP in senior leadership at the organisation means for primary care as the NHS shifts focus towards community-based care and neighbourhood health teams. He explains how NICE is working to accelerate guidance approvals, how guidelines can be made more accessible for frontline clinicians managing patients with complex multi-morbidities, and the role of the upcoming Single National Formulary - and what it will mean for GPs, pharmacists and primary care teams. Adrian also explains how NICE is adapting its evaluation frameworks for emerging health technologies, including AI tools and medical-grade wearables. This episode was presented by GPonline editor Emma Bower. It was produced by Czarina Deen. Useful links MHRA and NICE aligned pathway: how it's working in practice - article on NICE’s website Information about NICE’s lifecycle approach to guidance development The Pharmacists’ Summit - from MIMS Healthcare Network Two evenings of online learning on 30 November and 1 December for pharmacists working in primary care. For more information and to register for your free place visit: https://www.mimshealthcarenetwork.co.uk/mims-learning-live-digital-the-pharmacists-summit
The GPonline team discusses the latest news affecting general practice.
In this bonus episode of Talking General Practice Dr Netty Kinsella, uro-oncology nurse consultant and clinical lead for urology cancer diagnostics and active surveillance at The Royal Marsden NHS Foundation Trust, speaks to GPonline editor Emma Bower about urological cancer.